10-Q: Gilead Q3 2025 Earnings Soar on IP Sale, Reduced Impairments

Gilead Sciences reported a significant increase in net income and diluted EPS for Q3 and the first nine months of 2025, driven by a $400 million intellectual property sale and substantially lower impairment charges compared to the prior year.

Summary

• Total revenues increased 3% to $7.8 billion for the three months ended September 30, 2025, and 2% to $21.5 billion for the nine months ended September 30, 2025, compared to the same periods in 2024.
• Net income attributable to Gilead surged to $3.1 billion ($2.43 diluted EPS) for Q3 2025, up from $1.3 billion ($1.00 diluted EPS) in Q3 2024.
• For the nine months ended September 30, 2025, net income was $6.3 billion ($5.04 diluted EPS), a significant turnaround from a net loss of $1.3 billion ($-1.04 diluted EPS) in the same period of 2024.
• The substantial increase in net income was primarily due to the absence of a $1.8 billion IPR&D impairment charge in Q3 2024, lower acquired IPR&D expenses, and a $400 million revenue recognition from an intellectual property sale.
• HIV product sales grew 4% to $5.3 billion in Q3 2025 and 6% to $15.0 billion for the nine months, driven by Biktarvy (+6% in Q3, +7% in 9M) and Descovy (+20% in Q3, +30% in 9M).
• Liver Disease product sales increased 12% to $819 million in Q3 2025 and 3% to $2.4 billion for the nine months, largely due to Livdelzi and HBV products.
• Veklury sales decreased significantly by 60% to $277 million in Q3 2025 and 52% to $700 million for the nine months, reflecting lower COVID-19 hospitalizations.
• Oncology Cell Therapy sales declined 11% to $432 million in Q3 2025 and 7% to $1.4 billion for the nine months due to competitive headwinds, while Trodelvy sales increased 7% to $357 million in Q3 and 6% to $1.0 billion for the nine months.
• Biktarvy patent litigation with generic manufacturers Lupin, Laurus, and Cipla was settled, extending US generic entry for full dose Biktarvy until April 1, 2036, and pediatric dose until November 19, 2035 (if pediatric exclusivity granted).
• The Phase 3 ASCENT-07 study for Trodelvy in HR+/HER2metastatic breast cancer did not meet its primary endpoint of progression-free survival, though an early trend favored overall survival.
• A $190 million partial impairment charge was recognized in Q2 2025 for the bulevirtide IPR&D intangible asset due to competitive clinical data.
• The company declared a quarterly dividend of $0.79 per share, payable December 30, 2025, and authorized a new $6.0 billion stock repurchase program to commence after the current $5.0 billion program is completed.

Sentiment

Score: 7

Explanation: The sentiment is positive due to a strong financial rebound driven by reduced impairment charges and a significant IP sale, coupled with extended patent exclusivity for Biktarvy and progress in new HIV treatments. However, declines in Veklury and Cell Therapy sales, a clinical trial setback for Trodelvy, and ongoing legal challenges temper the overall optimism.

Positives

• Net income and diluted EPS saw substantial increases for both the three and nine months ended September 30, 2025, primarily due to reduced impairment charges and a $400 million revenue recognition from an intellectual property sale.
• HIV product sales demonstrated strong growth, with Biktarvy increasing 6% in Q3 2025 to $3.686 billion and Descovy increasing 20% to $701 million, driven by higher demand and patient switching.
• Liver Disease product sales grew 12% in Q3 2025 to $819 million, with Vemlidy sales up 21% to $280 million and 'Other Liver Disease' sales nearly doubling to $231 million.
• Settlement of Biktarvy patent litigation with Lupin, Laurus, and Cipla extends US generic entry for full dose Biktarvy until April 1, 2036, and pediatric dose until November 19, 2035, providing significant long-term exclusivity.
• Yeztugo (lenacapavir) for HIV PrEP received strong recommendation from the U.S. CDC guidelines, EC marketing authorization, and FDA approval for twice-yearly use, along with a partnership with the U.S. State Department and PEPFAR to deliver it to up to two million people.
• Trodelvy product sales increased 7% to $357 million in Q3 2025 and 6% to $1.013 billion for the nine months, indicating continued demand for the oncology treatment.
• The company completed the acquisition of Interius BioTherapeutics, Inc. for approximately $350 million, expanding its oncology pipeline with in vivo chimeric antigen receptor therapeutics.
• A new $6.0 billion stock repurchase program was authorized, demonstrating commitment to shareholder returns, following the ongoing $5.0 billion program.
• A settlement with a tax authority in October 2025 is anticipated to result in approximately $450 million of income tax benefit and a $530 million reduction in unrecognized tax benefits in Q4 2025.
• The U.S. enacted tax reform legislation through the One Big Beautiful Bill (OBBB) Act restored immediate expensing of domestic R&D and certain capital expenditures, which could be beneficial.

Negatives

• Product sales decreased 2% for the three months ended September 30, 2025, primarily due to significant declines in Veklury and Cell Therapy sales.
• Veklury product sales plummeted 60% to $277 million in Q3 2025 and 52% to $700 million for the nine months, attributed to lower rates of COVID-19-related hospitalizations.
• Cell Therapy product sales (Tecartus and Yescarta) decreased 11% to $432 million in Q3 2025 and 7% to $1.381 billion for the nine months, reflecting ongoing competitive headwinds.
• The Phase 3 ASCENT-07 study of Trodelvy for HR+/HER2metastatic breast cancer did not meet its primary endpoint of progression-free survival, representing a clinical setback for this indication.
• A clinical hold was placed on HIV treatment trials of investigational drug candidates GS-1720 and/or GS-4182 (WONDERS-1 and WONDERS-2).
• A $190 million partial impairment charge was recognized in Q2 2025 for the bulevirtide IPR&D intangible asset due to new competitive clinical data, indicating a potentially more challenging market.
• Genvoya and Odefsey HIV product sales declined by 16% and 15% respectively in Q3 2025, and 13% and 10% for the nine months, indicating shifts in the HIV treatment landscape.
• Sofosbuvir/Velpatasvir (Liver Disease) sales decreased 20% in Q3 2025 and 21% for the nine months, partly due to lower average realized price for chronic HCV products.
• Operating cash flow decreased 15% for the nine months ended September 30, 2025, primarily due to higher inventory build-up and unfavorable timing of collections on increased sales.

Risks

• Inability to sustain or increase sales of HIV products due to market share gains by competitive products, including generics, or failure to introduce new HIV medications.
• Significant challenges in advancing novel and personalized CAR T-cell therapies like Yescarta or Tecartus, including manufacturing, managing side effects, securing supply, and potential regulatory actions like class labeling changes (e.g., boxed warning for secondary T-cell malignancies).
• High rate of failure inherent in the discovery and development of new products, leading to substantial R&D expenses without assurance of recouping investments or commercial success.
• Difficulties in accurately forecasting product sales due to unpredictable demand, fluctuations in purchasing patterns, and wholesaler inventories, potentially leading to product shortages or excess inventory write-offs.
• Significant competition from global pharmaceutical and biotechnology companies, specialized firms, and generic drug manufacturers, affecting pricing and market share.
• Pricing and reimbursement pressures from government agencies and other third parties, including the impact of the Inflation Reduction Act (IRA) and the One Big Beautiful Bill (OBBB) Act, which could increase payment obligations, limit prices, and reduce profitability.
• Adverse impacts from the importation of products from lower-price markets or the distribution of illegally diverted or counterfeit versions of products, potentially harming patients, reputation, and revenues.
• Risks in clinical trials, including unfavorable results (e.g., Trodelvy's ASCENT-07 study not meeting primary endpoint), delays, enrollment issues, safety concerns, and potential non-approval or significant restrictions by regulatory authorities.
• Inability to obtain materials or supplies necessary for clinical trials or manufacturing, or facing manufacturing difficulties, delays, or interruptions, including at third-party manufacturers, which could limit revenue generation.
• Dependence on compliance with complex FDA and comparable international regulations, with failure to obtain broad approvals or maintain compliance potentially delaying or halting commercialization.
• Exposure to evolving laws, regulations, and legislative actions applicable to the healthcare industry, including anti-kickback, false claims, data privacy, and potential new legislation like the BIOSECURE Act or ABC Safe Drug Act, which could increase costs or limit operations.
• Inability to obtain and defend patents and other intellectual property rights, or operating without infringing upon third-party rights, leading to potential litigation, invalidation of patents, or required licensing.
• Potentially significant liability and increased expenses from ongoing litigation and government investigations, including antitrust, product liability, and qui tam lawsuits, with uncertain outcomes.
• Adverse effects on global operations due to foreign currency exchange rate fluctuations, interest rate changes, inflation, anti-bribery laws, political instability, and increasing use of social media platforms.
• Negative impacts from climate change and related natural disasters, as well as legal, regulatory, or market measures to address climate change, affecting operations, facilities, and supply chain.
• Risks associated with engaging in business acquisitions, licensing arrangements, collaborations, and other strategic transactions, including integration challenges, failure to realize anticipated benefits, and potential impairment charges.
• Failure of U.S. manufacturing and R&D investments to achieve intended benefits due to construction delays, cost inflation, supply chain constraints, and regulatory compliance issues.
• Changes in the effective income tax rate due to shifts in earnings mix, valuation of deferred tax assets/liabilities, new taxes, or changes in tax laws and interpretations.

Future Outlook

The company anticipates recognizing approximately $450 million of income tax benefit and a corresponding $530 million reduction in unrecognized tax benefits in Q4 2025 due to a tax authority settlement and the One Big Beautiful Bill Act. No material income tax payments are anticipated for the remainder of 2025. While the Phase 3 ASCENT-07 study for Trodelvy in HR+/HER2metastatic breast cancer did not meet its primary endpoint, the company currently does not anticipate an impairment of the associated intangible asset, but potential future adverse changes in estimated Trodelvy revenues could lead to impairments. The company expects to continue experiencing fluctuations in non-retail customer purchasing patterns and potential inventory draw-downs in subsequent first quarters. The full impact of the Inflation Reduction Act on the business remains uncertain but is anticipated to increase payment obligations, limit prices, and increase rebates, reducing profitability. The OBBB Act's changes to Medicaid and potential expiration of ACA premium subsidies could decrease health insurance coverage for patients. The company plans to continue investing in its business and R&D pipeline, pursue select partnerships and business development, grow its dividend, and repurchase shares.

Management Comments

• We are committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, coronavirus disease 2019 (COVID-19), cancer and inflammation.
• Our capital priorities include: (i) investing in our business and R&D pipeline, (ii) continuing select partnerships and business development transactions, (iii) growing our dividend over time and (iv) repurchasing shares to offset dilution and opportunistically reduce share count.

Industry Context

Gilead's performance reflects broader trends in the biopharmaceutical industry, including the ongoing shift in HIV treatment paradigms towards newer, more convenient regimens like Biktarvy and the emergence of long-acting PrEP options like Yeztugo. The significant decline in Veklury sales highlights the decreasing impact of COVID-19-related hospitalizations on pharmaceutical revenues as the pandemic wanes and alternative treatments/vaccines become widespread. The oncology segment faces intense competition, as evidenced by the mixed results for Trodelvy and the need for strategic collaborations and acquisitions (Interius, Kymera) to bolster the pipeline. Pricing and reimbursement pressures, particularly from U.S. government initiatives like the Inflation Reduction Act and the OBBB Act, remain a significant industry-wide challenge, potentially impacting future profitability across the sector. The extension of Biktarvy's patent exclusivity provides a competitive advantage against generic entrants, a common threat in the mature pharmaceutical market.

Comparison to Industry Standards

• Gilead's Biktarvy patent settlement, extending U.S. exclusivity until April 1, 2036, is a significant win, providing a longer runway compared to many blockbuster drugs facing earlier generic competition, such as Humira (AbbVie) which saw biosimilar entry in early 2023.
• The strong growth of Biktarvy and Descovy in HIV sales aligns with the industry trend of newer, more effective, and convenient single-tablet regimens dominating the market, similar to ViiV Healthcare's Dovato and Triumeq.
• The substantial decline in Veklury sales (-60% in Q3 2025) is consistent with the broader pharmaceutical industry's reduced revenue from COVID-19 treatments as the pandemic evolves and hospitalizations decrease, mirroring trends seen with other COVID-19 related products.
• The failure of Trodelvy's ASCENT-07 study to meet its primary endpoint in HR+/HER2metastatic breast cancer is a setback, but the observed early trend in overall survival could still offer a competitive profile, though it falls short of the clear-cut efficacy demonstrated by leading ADCs like Enhertu (Daiichi Sankyo/AstraZeneca) in similar settings.
• Gilead's strategic acquisitions (e.g., Interius BioTherapeutics) and collaborations (e.g., Kymera Therapeutics, LEO Pharma) are in line with industry practices for large pharmaceutical companies seeking to replenish pipelines and expand into new therapeutic modalities like CAR T-cell therapies and molecular glue degraders, similar to recent deals by Bristol Myers Squibb or Merck.
• The company's commitment to a $32 billion investment in U.S. manufacturing and R&D through 2030 is a substantial long-term capital allocation, comparable to large-scale investments by peers like Pfizer or Eli Lilly to enhance domestic production and innovation capabilities.

Management Changes

Corporate Governance

Legal Proceedings

• Biktarvy Patent Litigation: Lawsuits against Lupin Ltd., Laurus Labs, and Cipla Ltd. were dismissed in October 2025 based on negotiated settlement agreements, preventing generic entry for full dose Biktarvy in the U.S. before April 1, 2036, and for pediatric dose before November 19, 2035 (if pediatric exclusivity granted) or May 19, 2035 (if not).
• Veklury Patent Litigation: A lawsuit was filed against Aspiro Pharma Ltd. in July 2025 in the U.S. District Court of New Jersey to enforce and defend intellectual property against an ANDA submission for a generic version of Veklury.
• HIV Antitrust and Consumer Protection Class Action Lawsuits: Consolidated lawsuits are pending in the U.S. District Court for the Northern District of California, alleging restraint of competition for various HIV drugs. Claims with direct purchaser class and retailer opt-out plaintiffs were settled for $525 million in May 2023. A jury returned a verdict in Gilead's favor on Phase I allegations (Truvada and Atripla) in June 2023, which is currently under appeal (oral argument in October 2025), with Phase II (Complera) stayed pending the appeal.
• Aetna Antitrust Lawsuit: A separate opt-out lawsuit filed by Aetna, Inc. in January 2022 in California state court, with allegations substantively similar to the class actions. Trial is scheduled for January 2027, and Gilead has filed a writ petition to the Court of Appeal regarding a denied motion for judgment on the pleadings.
• New Mexico Attorney General Antitrust Lawsuit: A lawsuit filed in February 2021 alleging restraint of competition was dismissed with prejudice in September 2025.
• Product Liability Lawsuits: Approximately 23,000 active plaintiffs are involved in putative class action and various product liability lawsuits in California and Missouri, alleging kidney, bone, and/or tooth injuries from Viread, Truvada, Atripla, Complera, and Stribild. A $39 million payment was agreed upon with a group of ~2,470 plaintiffs in the federal case, with the first bellwether trial for remaining federal cases set for March 2027. A Missouri class action certification motion is under advisement.
• Qui Tam Litigation (Former Sales Employee): A lawsuit alleging violations of the federal False Claims Act and state false claims acts related to hepatitis C virus sales and marketing activities and donations was dismissed in September 2025, but the relator has appealed the ruling.
• Qui Tam Litigation (Health Choice Advocates, LLC): A new action commenced in October 2023 (after voluntary dismissal of a prior suit) with the Texas Attorney General intervening, alleging violations of the Texas Medicare Fraud Prevention Act. Trial is scheduled for June 2026.

Stakeholder Impact

• Shareholders: Positive impact from increased net income and EPS, extended patent exclusivity for Biktarvy, new stock repurchase program, and consistent dividend payments. Potential negative impact from clinical trial setbacks and ongoing litigation costs.
• Patients: Positive impact from new HIV PrEP options (Yeztugo) and continued development in HIV and oncology. Potential negative impact from clinical holds on HIV treatment trials and the failure of Trodelvy's ASCENT-07 study to meet its primary endpoint in a specific breast cancer indication.
• Employees: Potential impact from restructuring charges related to workforce reductions. The amended severance plan provides updated benefits for eligible employees.
• Customers (Wholesalers/Distributors): Fluctuations in purchasing patterns and inventory levels can affect their operations and orders from Gilead.
• Regulatory Authorities: Ongoing interactions and compliance requirements, including responses to clinical holds and patent challenges. The company's compliance with evolving laws (e.g., IRA, OBBB Act) will impact its operations.
• Government Agencies: Impacted by the company's compliance with pricing and reimbursement regulations, including Medicaid rebates and 340B program changes. The tax settlement will affect government revenue.

Next Steps

• Continue to vigorously oppose the appeal and defend against Phase II claims in the HIV antitrust litigation.
• Vigorously defend against the Aetna antitrust lawsuit, with trial scheduled for January 2027.
• Vigorously defend against product liability lawsuits, with the first federal bellwether trial set for March 2027.
• Vigorously defend against the appealed qui tam lawsuit by a former sales employee.
• Vigorously defend against the Health Choice Advocates, LLC qui tam lawsuit, with trial scheduled for June 2026.
• Continue to enforce and defend intellectual property against Aspiro Pharma Ltd.'s ANDA challenge for Veklury.
• Monitor the appeal of the Phase I verdict in HIV antitrust litigation, with oral argument having taken place in October 2025.
• Continue to evaluate the potential impact of the Inflation Reduction Act and the One Big Beautiful Bill Act on the business.
• Complete the current $5.0 billion stock repurchase program and commence the new $6.0 billion program.
• Pay the quarterly dividend of $0.79 per share on December 30, 2025.
• Recognize anticipated $450 million income tax benefit and $530 million reduction in unrecognized tax benefits in Q4 2025 due to tax settlement and OBBB Act.
• Continue to implement new ERP and other related systems in phases over the next few years.
• Continue to invest in the business and R&D pipeline, pursue select partnerships and business development transactions, and grow the dividend over time.

Key Dates

Recommendation

Gilead's Q3 2025 results show a strong financial rebound, largely driven by non-recurring factors like reduced impairment charges and a significant IP sale, which mask some underlying product sales challenges. While the extended patent exclusivity for Biktarvy is a major long-term positive, providing revenue stability, the declines in Veklury and Cell Therapy sales, coupled with the clinical setback for Trodelvy in a key breast cancer indication, present headwinds. The company's robust capital allocation strategy, including dividends and share repurchases, supports shareholder value. However, substantial ongoing legal proceedings and the uncertain impact of evolving healthcare legislation (IRA, OBBB Act) introduce considerable risk. Given the mixed operational performance, significant one-time gains, and persistent legal and regulatory uncertainties, a 'hold' recommendation is appropriate for investors to observe the sustained growth of key products and the resolution of legal and financial policy impacts before making further commitments.

Keywords

HIV, Biktarvy, Descovy, Yeztugo, Oncology, Trodelvy, Cell Therapy, Veklury, Liver Disease, Seladelpar, Biopharmaceutical, SEC Filing, Earnings Report, Patent Litigation, R&D, Clinical Trials, Acquisition, Capital Allocation, Share Repurchase, Dividend